LivaNova (NASDAQ:LIVN) Director Francesco Bianchi Sells 1,800 Shares

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the transaction, the director directly owned 7,228 shares of the company’s stock, valued at approximately $547,521. This represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

LivaNova Price Performance

LIVN stock opened at $73.90 on Thursday. LivaNova PLC has a 12 month low of $41.01 and a 12 month high of $75.82. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The company has a 50-day moving average price of $66.16 and a 200 day moving average price of $64.05. The stock has a market cap of $4.06 billion, a PE ratio of 37.90 and a beta of 0.82.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. During the same quarter last year, the business posted $0.88 EPS. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Equities research analysts anticipate that LivaNova PLC will post 3.72 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LIVN shares. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Needham & Company LLC lifted their price objective on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Robert W. Baird decreased their price objective on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Stifel Nicolaus set a $80.00 price objective on shares of LivaNova in a report on Wednesday, February 25th. Finally, Piper Sandler reiterated an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a report on Thursday, February 19th. Six equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $79.38.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of LIVN. Hantz Financial Services Inc. raised its stake in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after acquiring an additional 267 shares in the last quarter. State of Wyoming bought a new position in shares of LivaNova during the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC raised its stake in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after acquiring an additional 639 shares in the last quarter. Quarry LP bought a new position in shares of LivaNova during the 3rd quarter worth approximately $36,000. Finally, UMB Bank n.a. raised its stake in shares of LivaNova by 63.0% during the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after acquiring an additional 306 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.